KR20220094155A - Pharmaceutical composition for the prevention or treatment of cancer containing nanovesicles derived from the strains of Lactobacillus Sakei as an active ingredient - Google Patents

Abstract

The present invention relates to a composition for preventing or treating cancer comprising nanovesicles derived from a strain of Lactobacillus sakei isolated from kimchi as an active ingredient. Since nanovesicles derived from the strain of Lactobacillus sakei according to the present invention can increase the death of various cancer cells such as lung cancer, bladder cancer, etc., and increase an inflammatory substance (TNF-α) of macrophages, thereby being able to be usefully used as the composition for treating, preventing or alleviating cancer of human or animal.

Description

Pharmaceutical composition for the prevention or treatment of cancer containing nanovesicles derived from Lactobacillus Sakei strain as an active ingredient {Pharmaceutical composition for the prevention or treatment of cancer containing nanovesicles derived from the strains of Lactobacillus Sakei as an active ingredient}

The present invention relates to a composition for preventing or treating cancer comprising, as an active ingredient, nanovesicles derived from a Lactobacillus sakeai strain isolated from kimchi.

Cancer has the highest mortality rate worldwide and is the second most common cause of death in Western societies after cardiovascular disease. In particular, due to the westernization of dietary habits, high-fat diets are common, and due to the rapid increase in environmental pollutants and the increase in alcohol consumption, colorectal cancer, breast cancer, prostate cancer, etc. are continuously increasing. Lung cancer is on the rise due to the increase in cancer and air pollution. In this situation, there is an urgent need to create anticancer substances that can contribute to the promotion of human health, the improvement of the quality of healthy life, and the promotion of human health by enabling the early prevention and treatment of cancer.

On the other hand, lactic acid bacteria are widely distributed in the oral cavity, intestine, vagina, feces, and fermented foods such as kimchi of humans and animals, and are closely related to the health of humans and animals. Lactobacillus has various health-promoting effects such as bowel action, suppression of harmful bacteria, immune regulation, lowering blood cholesterol, and anti-cancer.

In addition, it has been reported that prokaryotic cells such as bacteria and eukaryotic cells, which are host cells such as humans, secrete vesicles out of the cell, and the secreted endoplasmic reticulum performs various functions. The extracellular vesicles secreted from bacteria contain endotoxin (lipopolysaccharide; LPS) and bacteria-derived proteins and genes. It has been reported that extracellular vesicles have been found in various secretions, feces, or tissue washing fluids of humans or animals, and the extracellular vesicles present in tissues are known to reflect the state of the tissue that secretes ER, and it is used to diagnose and diagnose diseases and It has been reported that it can be used for treatment.

Currently, Korean Patent No. 10-2136772 discloses the anticancer activity of Lactobacillus sakeai strain, and Korean Patent Publication No. 10-2019-0105522 describes nanovesicles derived from Lactobacillus genus bacteria and uses thereof. , No specific experimental examples or examples confirming that the composition containing the Lactobacillus Sakeai strain-derived nano-endoplasmic reticulum is effective in preventing or treating cancer has not been described.

Korean Patent Registration No. 10-2136772 Korean Patent Publication No. 10-2019-0105522

It is an object of the present invention to provide a pharmaceutical composition for the prevention or improvement of cancer comprising the Lactobacillus Sakeai strain-derived nanovesicles as an active ingredient.

In addition, another object of the present invention is to provide a food composition for the prevention or improvement of cancer comprising the Lactobacillus Sakeai strain-derived nanovesicles as an active ingredient.

In addition, another object of the present invention is to provide a feed composition for the prevention or improvement of cancer comprising the Lactobacillus Sakeai strain-derived nanovesicles as an active ingredient.

Accordingly, the present inventors received Lactobacillus Sakei, WIKIM30, accession number KCCM11878P) deposited at the Korea Microbial Conservation Center, and separated the nanovesicles therefrom using a composition containing it as an active ingredient for colorectal cancer As a result of trying to confirm the preventive and therapeutic effects on various carcinomas, such as, the present invention was completed by confirming the excellent preventive and therapeutic effects.

In order to achieve the above object, there is provided a pharmaceutical composition for the prevention or treatment of cancer comprising the Lactobacillus Sakeai strain-derived nanovesicles as an active ingredient.

In addition, the present invention provides a food composition for preventing or improving cancer comprising the Lactobacillus sakeai strain-derived nanovesicles as an active ingredient.

In addition, the present invention provides a feed composition for preventing or improving cancer in livestock, comprising the Lactobacillus sakeai strain-derived nanovesicles as an active ingredient.

Nanovesicles derived from the Lactobacillus permentum strain according to the present invention can increase the death of various cancer cells, such as lung cancer and bladder cancer, and the inflammatory substance (TNF-alpha) of macrophages, so it can be used for treatment, prevention or improvement of human or animal cancer. It can be usefully used as a composition for use.

1 is a view showing a graph measuring the cell growth rate (cell viability assay) after treating the Lactobacillus Sakeai strain-derived nano-ER in the lung cancer A549 cell line according to an embodiment of the present invention.
2 is a view showing a graph measuring the cell growth rate (cell viability assay) after treating the Lactobacillus Sakeai strain-derived nano-ER in the bladder cancer T24 cell line according to an embodiment of the present invention.

Hereinafter, the present invention will be described in more detail through examples. These examples are only for illustrating the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention. .

The composition comprising the Lactobacillus sakeai strain-derived nanovesicles of the present invention as an active ingredient has a preventive or therapeutic effect on cancer, and can be used as a pharmaceutical composition.

The Lactobacillus Sakei strain may be Lactobacillus Sakei WIKIM30 (Lactobacillus Sakei, WIKIM30, accession number KCCM11878P), and nanovesicles isolated therefrom were used, but not limited thereto.

Lactobacillus Sakei WIKIM30 (Lactobacillus Sakei, WIKIM30) of the present invention is a lactic acid bacteria strain derived from kimchi. The Lactobacillus Sakeai WIKIM30 is a probiotic and has a general intestinal effect and immune enhancing effect of lactic acid bacteria.

The Lactobacillus sakeai WIKIM30 is characterized in that it has a nucleic acid sequence of SEQ ID NO: 1 (SEQ ID NO: 1).

In the present invention, 'probiotics' is understood to mean 'living microorganisms that have a beneficial effect on the health of the host by improving the intestinal microbial environment of the host in the gastrointestinal tract of animals including humans'. Probiotics are living microorganisms with probiotic activity, and when fed to humans or animals in the form of single or complex strains in the form of dried cells or fermentation products, it can have a beneficial effect on the intestinal flora of the host.

The cancers include colorectal cancer, bladder cancer, breast cancer, black tumor, thyroid cancer, parathyroid cancer, rectal cancer, throat cancer, laryngeal cancer, esophageal cancer, pancreatic cancer, stomach cancer, tongue cancer, skin cancer, brain tumor, uterine cancer, double gallbladder cancer, oral cancer, colon cancer, perianal cancer, blood It may be any one cancer selected from the group consisting of cancer, liver cancer, and lung cancer, but is not limited thereto.

The nanovesicles refer to structures made of nano-sized membranes secreted by various bacteria. The nanovesicles are derived from the Lactobacillus sakeai strain and may have an average diameter of 1 to 1000 nm, preferably 10 to 500 nm, but is not limited thereto.

The nanovesicles may be isolated from the Lactobacillus sakeai strain by a natural or artificial method, and any method commonly used in the art may be used without limitation in the artificial method. For example, a commercially available exosome isolation kit (eg, EXO-BB, ExoQuick®-ULTRA, ExoQuick®-TC, CapturemTM Exosome Isolation Kit, Total Exosome Isolation Kit, ExoTrapTM Exosome Isolation Spin Column Kit, Exo2DTM, etc.) is used, or a solution Separation according to the difference in specific gravity between resistant components (eg, centrifugation), separation according to size (eg, ultrafiltration or vacuum filter), separation based on affinity for a specific substrate (eg, affinity chromatography), Preferably, it may be a precipitation separation method using a separation kit, but is not limited thereto, and any method commonly used in the art may be used without limitation as a separation method based on the intrinsic properties of the target material in a heterogeneous sample.

The composition comprising the endoplasmic reticulum derived from the Lactobacillus sakeai WIKIM30 strain according to the present invention may be administered orally or parenterally. In the case of parenteral administration, intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, endothelial administration, topical administration, intranasal administration, intrapulmonary administration and rectal administration, etc. may be administered, preferably by intravenous injection. may be administered, but is not limited thereto.

A suitable dosage of the composition may be prescribed in various ways depending on factors such as formulation method, administration mode, age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity of the patient.

When the composition of the present invention is used as a pharmaceutical composition, the pharmaceutical composition of the present invention may be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the active ingredient, and the adjuvant includes an excipient, bog Release, sweetener, binder, coating agent, swelling agent, lubricant, lubricant or flavoring agent and the like can be used.

The pharmaceutical composition may be preferably formulated as a pharmaceutical composition by including one or more pharmaceutically acceptable carriers in addition to the active ingredients described above for administration.

For example, for formulation in the form of a tablet or capsule, the active ingredient may be combined with an orally, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. In addition, if desired or required, suitable binders, lubricants, disintegrants and color-developers may also be included in the mixture. Suitable binders include, but are not limited to, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tracacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate. ate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methylcellulose, agar, bentonite, xanthan gum, and the like. In the composition formulated as a liquid solution, acceptable pharmaceutical carriers include sterile and biocompatible, saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostats may be added as needed. In addition, diluents, dispersants, surfactants, binders and lubricants may be additionally added to form an injectable formulation such as an aqueous solution, suspension, emulsion, etc., pills, capsules, granules or tablets.

Furthermore, by using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA by an appropriate method in the field, it can be preferably formulated according to each disease or component.

The composition comprising nanovesicles derived from Lactobacillus Sakei WIKIM30 (Lactobacillus Sakei, WIKIM30, accession number KCCM11878P) strain of the present invention as an active ingredient can be used as a food composition for preventing or improving cancer.

The food composition may be in the form of a health functional food.

The above "health functional food" means food manufactured and processed using raw materials or ingredients useful for the human body in accordance with the Health Functional Food Act (Article 3, No. 1), and "functionality" means Controlling nutrients for the structure and function of the human body or obtaining useful effects for health purposes such as physiological action (Article 2).

The food composition may additionally contain food additives, and the suitability as a "food additive" is determined according to the general rules and general test methods of the Food Additives Code approved by the Ministry of Food and Drug Safety, unless otherwise specified. and criteria.

Items listed in the "Food Additives Code", for example, chemical synthetic products such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as depigmentation, licorice extract, crystalline cellulose, guar gum, L- Mixed preparations such as sodium glutamate preparation, noodle-added alkali preparation, preservative preparation, and tar color preparation can be mentioned.

Foods containing the active ingredient of the present invention include bread, rice cakes, dried fruits, candies, chocolates, chewing gum, confectionery products such as jams, ice cream products, ice cream products, ice cream products such as ice cream powder milk, low-fat milk, lactose-decomposed milk, Processed milk, goat milk, fermented milk, buttermilk, concentrated milk, milk cream, butter oil, natural cheese, processed cheese, milk powder, milk products such as whey Processed meat products, processed eggs, meat products such as hamburgers Fish cakes, ham, Fish and meat products such as sausages, bacon, etc. Fish and meat products Ramen, dried noodles, raw noodles, fried noodles, luxurious dried noodles, improved soft noodles, frozen noodles, pastas, etc. Fruit drinks, vegetable drinks, carbonated drinks, soy milk, Beverages such as yogurt, lactic acid bacteria, mixed drinks, soy sauce, soybean paste, red pepper paste, chunjang, cheonggukjang, mixed soy sauce, vinegar, sauces, tomato ketchup, curry and seasonings such as dressings, margarine, shortening, and pizza, but limited to this it is not going to be

In addition to the above, the composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, It may include a carbonation agent used in carbonated beverages, and the like. In addition, the composition of the present invention may include fruit for the production of natural fruit juice, fruit juice beverage, and vegetable beverage. These components may be used independently or in combination.

The beverage composition including the active ingredient of the present invention is not particularly limited in other ingredients, and may contain various flavoring agents or natural carbohydrates as additional ingredients like conventional beverages. Examples of the aforementioned natural carbohydrates include monosaccharides (eg, glucose, fructose, etc.); disaccharides, (eg maltose, sucrose, etc.); and conventional sugars such as polysaccharides (eg, dextrin, cyclodextrin, etc.), and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatine, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. have.

In addition, the composition comprising the Lactobacillus Sakei WIKIM30 (Lactobacillus Sakei, WIKIM30, accession number KCCM11878P) strain-derived nanovesicles as an active ingredient of the present invention can be used as a feed composition for preventing or improving livestock cancer.

When the composition is prepared as a feed additive, the composition may be 20 to 90% highly concentrated or may be prepared in powder or granular form. The feed additive is an organic acid such as citric acid, humic acid, adipic acid, lactic acid, malic acid, sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate (polyphosphate), etc., polyphenol, catechin, alpha-tocopherol, rosemary Extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, any one or more of natural antioxidants such as phytic acid may be further included. When prepared as a feed, the composition may be formulated in the form of a conventional feed, and may include common feed ingredients together.

The feed and feed additives include grains such as milled or crushed wheat, oats, barley, corn and rice; plant protein feeds, such as feeds based on rape, soybean, and sunflower; animal protein feeds such as blood meal, meat meal, bone meal and fish meal; Sugar and dairy products, for example, may further include dry ingredients made of various powdered milk and whey powder, and may further include nutritional supplements, digestion and absorption enhancers, growth promoters, and the like.

The feed additive may be administered to the animal alone or in combination with other feed additives in an edible carrier. In addition, the feed additive can be easily administered to the animal as a top dressing, directly mixing them with animal feed, or in an oral formulation separate from the feed. When the feed additive is administered separately from animal feed, it may be combined with a pharmaceutically acceptable edible carrier as well known in the art to prepare an immediate release or sustained release formulation. Such edible carriers may be solid or liquid, for example cornstarch, lactose, sucrose, soybean flakes, peanut oil, olive oil, sesame oil and propylene glycol. When a solid carrier is used, the feed additive may be a tablet, capsule, powder, troche or sugar-containing tablet or top dressing in microdispersed form. When a liquid carrier is used, the feed additive may be in the form of a gelatin soft capsule, or a syrup or suspension, emulsion, or solution.

In addition, the feed and feed additives may contain adjuvants, for example, preservatives, stabilizers, wetting or emulsifying agents, solution accelerators, and the like. The feed additive may be used by being added to animal feed by immersion, spraying, or mixing.

The feed or feed additive of the present invention can be applied to a number of animal diets including mammals, poultry and fish.

Pigs, cows, horses, sheep, rabbits, goats, rodents and experimental rodents as the mammals, as well as rats, hamsters, and guinea pigs, can be used for pets (eg, dogs, cats), etc., and as the poultry, chicken, It can also be used for turkey, duck, geese, pheasant, and quail, and the like, and can be used for carp, crucian carp and trout as the fish, but is not limited thereto.

Example 1. Culture of the strain

Lactobacillus sakeai WIKIM30 (accession number KCCM11878P) received permission from the donor, the Korea Food Research Institute, and was distributed from the Korea Microorganism Conservation Center and tested.

0.1% of the received Lactobacillus Sakeai WIKIM30 strain was inoculated into 30 ml of a vegetable MRS liquid medium and cultured at 37° C. for 16 hours. After incubation, centrifuged at 3500 rpm for 10 minutes, the culture solution was stored separately for nano-ER separation, and the cells were washed three times with PBS (phosphate buffered saline) solution to remove the remaining medium components and used for the experiment.

Example 2. nano endoplasmic reticulum separation

The culture solution obtained after culturing the strain and 1M NaCl solution containing 16% PEG 6000 were mixed in equal amounts and reacted at 4°C for 15 hours. Thereafter, the reacted solution was centrifuged at 10,000 g, 4° C. for 20 minutes to obtain a nano-endoplasmic reticulum pellet. The nano-endoplasmic reticulum pellet was resuspensioned in 0.5M NaCl solution containing 5% PEG6000, washed, and centrifuged at 11,000 rpm at 4°C for 20 minutes. Thereafter, the supernatant was discarded and the pellet was resuspensioned in 1X PBS to finally separate Lactobacillus sakeai-derived nanovesicles.

3. Measurement result of cell viability assay for cancer cell lines

In the present invention, after culturing lung cancer cell line (A549) and bladder cancer (T24) cells, the cell growth rate of cells treated with Lactobacillus sakeai-derived nanovesicles was measured through crystal violet staining. Absorbance of cancer cells treated with particles derived from empty medium was confirmed for its anticancer activity based on 100% growth rate. To measure the cell growth rate, 1x10 ⁴ cells were plated on each cancer cell in a 96-well plate, and then cultured for 24 hours in 5% CO ₂ , 37°C cell incubator. Thereafter, the particles derived from the empty medium and the isolated nano-ER, or the strain were treated for 24 hours. After removing the culture medium, it was washed 3 times with 200 ul of PBS. The remaining cells were stained with 50 ul of crystal violet for 10 minutes, and then washed 3 times with PBS. After the plate was air-dried at room temperature for 30 minutes, crystal violet stained with 100% ethanol was dissolved in the cells, and the absorbance was measured in a spectrophotometer at 590 nm. The results are shown in FIGS. 1 and 2 .

1 and 2, in the group treated with Lactobacillus sakeai-derived nano-ER, cancer cell death was confirmed to be significantly increased compared to the group treated with particles derived from the common medium and the group treated with the strain.

In the A549 cell line treated with the Lactobacillus Sakei strain-derived nanovesicles, 47% (see FIG. 1) and 80% (see FIG. 2) in the T24 cell line showed a very excellent cell growth rate inhibitory effect, so that the It was confirmed that the cancer cell growth was more effectively inhibited than in the case of the cancer cell, thereby exhibiting anticancer activity.

Korea Microorganism Conservation Center (Overseas) KCCM11878P 20160805

<110> LISCURE BIOSCIENCES CO., LTD <120> Lactobacillus sakei WIKIM30 <130> WIKIM30 <150> KR 10-2020-0184534 <151> 2020-12-28 <160> 1 <170> KoPatentIn 3.0 <210> 1 <211> 1422 <212> DNA <213> Lactobacillus sakei <400> 1 ccggctttgg gtgttacaaa ctctcatggt gtgacgggcg gtgtgtacaa ggcccgggaa 60 cgtattcacc gcggcatgct gatccgcgat tactagcgat tccggcttca tgtaggcgag 120 ttgcagccta caatccgaac tgagaatggt tttaagagat tagctaaacc tcgcggtctc 180 gcaactcgtt gtaccatcca ttgtagcacg tgtgtagccc aggtcataag gggcatgatg 240 atttgacgtc gtccccacct tcctccggtt tgtcaccggc agtctcacta gagtgcccaa 300 ctaaatgctg gcaactagta ataagggttg cgctcgttgc gggacttaac ccaacatctc 360 acgacacgag ctgacgacaa ccatgcacca cctgtcactt tgtccccgaa gggaaagctc 420 tatctctaga gtggtcaaag gatgtcaaga cctggtaagg ttcttcgcgt tgcttcgaat 480 taaaccacat gctccaccgc ttgtgcgggc ccccgtcaat tcctttgagt ttcaaccttg 540 cggtcgtact ccccaggcgg agtgcttaat gcgttagctg cggcactgaa gggcggaaac 600 cctccaacac ctagcactca tcgtttacgg catggactac cagggtatct aatcctgttt 660 gctacccatg ctttcgagcc tcagcgtcag ttacagacca gacagccgcc ttcgccactg 720 gtgttcttcc atatatctac gcatttcacc gctacacat gagttccact gtcctcttct 780 gcactcaagt ttcccagttt ccgatgcact tcttcggttg agccgaaggc tttcacatca 840 gacttaagaa accgcctgcg ctcgctttac gcccaataaa tccggacaac gcttgccacc 900 tacgtattac cgcggctgct ggcacgtagt tagccgtggc tttctggttg gataccgtca 960 ctacctgatc agttactatc agatacattc ttctccaaca acagagtttt acgatccgaa 1020 aaccttcttc actcacgcgg cgttgctcca tcagactttc gtccattgtg gaagatccc 1080 tactgctgcc tcccgtagga gtctgggccg tgtctcagtc ccagtgtggc cgattaccct 1140 ctcaggtcgg ctatgcatca cggtcttggt gagcctttac ctcaccaact aactaatgca 1200 ccgcgggtcc atcctaaagt gatagccgaa accatctttc aaccctacac catgcggtgt 1260 taggttttat gcggtattag catctgtttc caaatgttat cccccacttt agggcaggtt 1320 acccacgtgt tactcacccg tccgccactc actcaaatgt ttatcaatca ggagcaagct 1380 ccttcaatct aaacgagagt gcgttcgact tgcatgtatt ag 1422

Claims (13)

A pharmaceutical composition for the prevention or treatment of cancer comprising the Lactobacillus Sakei strain-derived nanovesicles as an active ingredient. According to claim 1,
Lactobacillus Sakei strain is Lactobacillus Sakei WIKIM30 (Lactobacillus Sakei, WIKIM30, accession number KCCM11878P), characterized in that the strain, the prevention or treatment of cancer pharmaceutical composition. According to claim 1,
The nanovesicles have a diameter of 10 to 500 nm, characterized in that the composition for the prevention or treatment of cancer. According to claim 1,
The nanovesicles are naturally or artificially secreted from the Lactobacillus Sakeai strain, the composition for preventing or treating cancer. The method of claim 1,
Cancers include colorectal cancer, bladder cancer, breast cancer, melanoma, thyroid cancer, parathyroid cancer, rectal cancer, throat cancer, laryngeal cancer, esophageal cancer, pancreatic cancer, stomach cancer, tongue cancer, skin cancer, brain tumor, uterine cancer, head and gallbladder cancer, oral cancer, colon cancer, perianal cancer, blood cancer , A pharmaceutical composition for preventing or treating cancer, characterized in that it is liver cancer or lung cancer. According to claim 1,
The composition is characterized in that it can be administered by the method of oral administration or parenteral administration. 7. The method of claim 6,
The method of parenteral administration is intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, endothelial administration, topical administration, intranasal administration, intrapulmonary administration or rectal administration, pharmaceutical composition for the prevention or treatment of cancer . A food composition for the prevention or improvement of cancer comprising the Lactobacillus Sakei strain-derived nanovesicles as an active ingredient. 9. The method of claim 8,
Lactobacillus Sakei strain is Lactobacillus Sakei WIKIM30 (Lactobacillus Sakei, WIKIM30, accession number KCCM11878P), characterized in that the strain, cancer prevention or improvement food composition. 9. The method of claim 8,
The food is a health functional food, a food composition for the prevention or improvement of cancer. A feed composition for preventing or improving livestock cancer, comprising, as an active ingredient, a Lactobacillus Sakeai strain-derived nanovesicle. 12. The method of claim 11,
Lactobacillus Sakei strain is Lactobacillus Sakei WIKIM30 (Lactobacillus Sakei, WIKIM30, accession number KCCM11878P), characterized in that the strain, cancer prevention or improvement of livestock feed composition. 12. The method of claim 11,
The livestock is pig, cow, horse, sheep, rabbit, goat, rat, hamster, guinea pig, dog, cat, chicken, turkey, duck, goose, pheasant, quail, carp, any one selected from the group consisting of crucian carp and trout which is, a feed composition for preventing or improving cancer in livestock.

Images